ENTRY       D09783                      Drug
NAME        Tofacitinib citrate (JAN/USAN);
            Tasocitinib citrate;
            Xeljanz (TN)
PRODUCT     XELJANZ (Pfizer Laboratories Div Pfizer)
            XELJANZ (U.S. Pharmaceuticals)
FORMULA     C16H20N6O. C6H8O7
EXACT_MASS  504.1969
MOL_WEIGHT  504.4931
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG02020  JAK inhibitor
            Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 3999
            ATC code: L04AA29
            Chemical structure group: DG00742
            Product (DG00742): D09783<JP/US>
EFFICACY    Antirheumatic, Janus kinase (JAK) inhibitor
  DISEASE   Rheumatoid arthritis [DS:H00630]
            Psoriatic arthritis [DS:H01656]
            Ankylosing spondylitis [DS:H01674]
            Ulcerative colitis [DS:H01466]
            Juvenile idiopathic arthritis [DS:H01672]
COMMENT     Treatment of immunological disorders
TARGET      JAK1 [HSA:3716] [KO:K11217]
            JAK2 [HSA:3717] [KO:K04447]
            JAK3 [HSA:3718] [KO:K11218]
            TYK2 [HSA:7297] [KO:K11219]
  PATHWAY   hsa04062(3717+3718)  Chemokine signaling pathway
            hsa04630(3716+3717+3718+7297)  JAK-STAT signaling pathway
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2C19 [HSA:1557]
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA29 Tofacitinib
                  D09783  Tofacitinib citrate (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               JAK Inhibitors
                Tofacitinib
                 D09783  Tofacitinib citrate (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D09783  Tofacitinib citrate (JAN/USAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                DG00742  Tofacitinib
                 D09783  Tofacitinib citrate
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               DG00742  Tofacitinib
                D09783  Tofacitinib citrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00742  Tofacitinib
                 D09783  Tofacitinib citrate
            Drug classes [BR:br08332]
             Immunological agent
              DG02020  JAK inhibitor
               D09783  Tofacitinib citrate
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D09783  Tofacitinib citrate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               JAK family
                JAK1
                 D09783  Tofacitinib citrate (JAN/USAN) &lt;JP/US&gt;
                JAK2
                 D09783  Tofacitinib citrate (JAN/USAN) &lt;JP/US&gt;
                JAK3
                 D09783  Tofacitinib citrate (JAN/USAN) &lt;JP/US&gt;
                TYK2
                 D09783  Tofacitinib citrate (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09783
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09783
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09783
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09783
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09783
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                DG00742  Tofacitinib
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               DG00742  Tofacitinib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00742  Tofacitinib
DBLINKS     CAS: 540737-29-9
            PubChem: 124490523
            ChEBI: 71197
            LigandBox: D09783
ATOM        36
            1   C1x C    24.2200  -16.0300
            2   N1y N    24.2200  -17.4300
            3   C1x C    25.4324  -18.1300
            4   C1y C    26.6449  -17.4300
            5   C1y C    26.6449  -16.0300
            6   C1x C    25.4324  -15.3300
            7   C5a C    23.0076  -18.1300
            8   C1b C    21.8121  -17.4396
            9   C3b C    20.6247  -18.1251
            10  O5a O    23.0075  -19.5298
            11  N3a N    19.4123  -18.8251
            12  C1a C    27.8760  -15.3190
            13  N1c N    27.8760  -18.1410
            14  C1a C    29.0812  -17.4453
            15  C8y C    27.8757  -19.5299
            16  N5x N    26.6514  -20.2366
            17  C8x C    26.6512  -21.6366
            18  N5x N    27.8635  -22.3367
            19  C8y C    29.0879  -21.6301
            20  C8y C    29.0881  -20.2301
            21  N4x N    30.4193  -22.0629
            22  C8x C    31.2424  -20.9304
            23  C8x C    30.4196  -19.7976
            24  C6a C    34.0900  -17.9900
            25  C1b C    35.3024  -18.6900
            26  O6a O    32.8776  -18.6900
            27  O6a O    34.0900  -16.5900
            28  C1d C    36.4979  -17.9996
            29  C1b C    37.6853  -18.6851
            30  C6a C    37.6853  -20.0851
            31  O6a O    36.4518  -20.7974
            32  O6a O    38.8807  -20.7754
            33  C6a C    37.1979  -16.7872
            34  O6a O    36.4979  -15.5747
            35  O6a O    38.5699  -16.7874
            36  O1a O    35.7979  -16.7872
BOND        37
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     2   7 1
            8     7   8 1
            9     8   9 1
            10    7  10 2
            11    9  11 3
            12    5  12 1 #Up
            13    4  13 1 #Up
            14   13  14 1
            15   13  15 1
            16   15  16 2
            17   16  17 1
            18   17  18 2
            19   18  19 1
            20   19  20 2
            21   15  20 1
            22   19  21 1
            23   21  22 1
            24   22  23 2
            25   20  23 1
            26   24  25 1
            27   24  26 1
            28   24  27 2
            29   25  28 1
            30   28  29 1
            31   29  30 1
            32   30  31 2
            33   30  32 1
            34   28  33 1
            35   33  34 1
            36   33  35 2
            37   28  36 1
///
